PETACH TIKVA, Israel, Jan. 27, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. (Nasdaq:MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that at 10:30 AM ET on Tuesday, February 10, 2015, Mr. Nissim Mashiach, Macrocure's President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference in New York City.
To view a live webcast of the Company's presentation, please visit Macrocure's Investor Relations website at http://investor.macrocure.com under 'Events & Presentations'. The webcast will be archived and available for 90 days.
About Macrocure Ltd.
Founded in 2008, Macrocure Ltd. is a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as DFUs and VLUs. The Company's novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body's own wound healing and regenerative components directly into the wound itself.
CONTACT: Francesca M. DeMartino Investor Relations & Corporate Communications Macrocure Ltd. (310) 739-6476; firstname.lastname@example.org